Welcome to our dedicated page for Reviva Pharmaceutcls Hldgs news (Ticker: RVPH), a resource for investors and traders seeking the latest updates and insights on Reviva Pharmaceutcls Hldgs stock.
Reviva Pharmaceuticals Holdings Inc (RVPH) focuses on developing novel therapies for central nervous system disorders and cardiometabolic diseases through its proprietary drug discovery platform. This page provides investors and industry observers with timely updates on clinical developments, regulatory milestones, and corporate announcements.
Access comprehensive coverage of Reviva's progress including clinical trial results, regulatory submissions, and strategic partnerships. Our curated news collection enables efficient tracking of the company's lead candidates like Brilaroxazine (RP5063) and RP1208 through critical development phases.
Key updates include progress in neuropsychiatric drug development, intellectual property advancements, and financial reporting. The resource serves investors requiring detailed insights into therapeutic pipeline maturation and market positioning within competitive CNS/pharma sectors.
Bookmark this page for streamlined access to Reviva's latest developments. Check regularly for authoritative reporting on clinical data releases, FDA communications, and research collaborations that shape the company's trajectory in biopharmaceutical innovation.
Reviva Pharmaceuticals Holdings (RVPH) reported a net loss of $8.5 million for 2021, equating to $0.58 per share, an increase from $3.8 million in 2020. As of December 31, 2021, the company had $29.7 million in cash, sufficient to fund operations through at least December 2022. Key developments include the initiation of a pivotal Phase 3 trial for brilaroxazine aimed at treating schizophrenia, with topline data expected by mid-2023. The company also plans to explore additional indications and funding opportunities for future studies.
Reviva Pharmaceuticals (NASDAQ: RVPH) has initiated dosing in its pivotal Phase 3 RECOVER trial for brilaroxazine, targeting acute schizophrenia. The trial aims to evaluate safety and efficacy in approximately 400 patients, with dosing set at 15 mg or 50 mg daily for 28 days. Following a successful Phase 2 study, Reviva plans to expand brilaroxazine's use to other neuropsychiatric conditions such as bipolar disorder and major depressive disorder. The FDA may consider a 'Superior Safety' label pending positive trial results, emphasizing the drug's potential in addressing significant treatment gaps in mental health.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) has received FDA clearance to proceed with two pivotal Phase 3 trials for its lead candidate, brilaroxazine, aimed at treating schizophrenia. The company anticipates trial initiation by the end of January 2022. Brilaroxazine, a novel serotonin and dopamine receptor modulator, previously demonstrated positive results in a Phase 2 study, reducing symptoms and displaying a strong safety profile. If successful, these trials may support a new drug application for brilaroxazine.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has announced that Laxminarayan Bhat, Ph.D., its Founder and CEO, will participate in upcoming conferences in January. These include the 11th Annual LifeSci Partners Corporate Access Event from January 5-7 and the H.C. Wainwright BioConnect Virtual Conference from January 10-13. Investors are invited to join virtual one-on-one meetings with the CEO. Reviva focuses on developing therapies for CNS, cardiovascular, metabolic, and inflammatory diseases, with drug candidates RP5063 and RP1208 in its pipeline.
Reviva Pharmaceuticals Holdings (RVPH) announced plans for two pivotal Phase 3 trials of brilaroxazine targeting schizophrenia by year-end 2021. The company reported $33.5 million in cash as of September 30, 2021, a significant increase from $0.35 million the previous year. Despite a net loss of $2.28 million for Q3 2021, Reviva is optimistic, citing a successful Phase 2 trial and plans for FDA submissions related to pulmonary conditions by Q1 2022. The ongoing efforts reflect Reviva's commitment to address unmet medical needs in CNS and pulmonary diseases.
Reviva Pharmaceuticals Holdings (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, Ph.D., will present at the Benzinga Healthcare Small Cap Conference on September 29-30, 2021. Dr. Bhat's presentation is scheduled for 1:55 – 2:15 pm ET on September 29. The conference will be virtual, allowing for remote participation. Reviva is focused on developing therapies for CNS, cardiovascular, and metabolic diseases. The conference will also host one-on-one investor meetings, offering opportunities for deeper engagement.
Reviva Pharmaceuticals (NASDAQ: RVPH) announced that its Founder and CEO, Laxminarayan Bhat, Ph.D., will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The conference will be virtual, allowing attendees to join remotely. An on-demand presentation will be available starting September 13 at 7am ET for 90 days. Reviva focuses on developing therapies for unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases, with key drug candidates RP5063 and RP1208.
Reviva Pharmaceuticals (NASDAQ: RVPH) closed a successful public offering, raising $34.5 million in gross proceeds, enhancing its liquidity for future clinical trials. The company plans to initiate a pivotal Phase 3 trial for its drug brilaroxazine in treating schizophrenia in Q4 2021. As of June 30, 2021, Reviva maintained a cash reserve of $35.8 million, compared to just $0.2 million a year earlier. Despite reporting a net loss of $2.6 million for Q2 2021, the funds secured will facilitate upcoming drug development and operations.
Reviva Pharmaceuticals (NASDAQ: RVPH) has been added to the Russell Microcap® Index as of June 28, 2021, following the annual reconstitution of the Russell U.S. Indexes. This inclusion, which identifies the largest U.S. stocks based on market capitalization, is expected to enhance Reviva's visibility among investors, particularly as the company plans to initiate a Phase 3 trial for its schizophrenia treatment later this year. The Russell Indexes are widely used by investment managers and benchmark over $9 trillion in assets.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has priced an upsized public offering of 8,000,000 shares of common stock at $3.75 each, along with investor warrants for an additional 6,000,000 shares. Gross proceeds are expected to total approximately $30 million, aimed at advancing the clinical development of brilaroxazine for treating schizophrenia and for general corporate purposes. The offering is set to close on June 1, 2021. Maxim Group LLC is the lead underwriter, with a 45-day option granted for underwriters to purchase additional shares.
